SCHEMBL11951600

SCHEMBL11951600

Cc1cc(C(C)C)ccc1-c1ccn(C)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.47
▸ KEAP1 Q14145 1/20 0.40
▸ KMT2A Q03164 1/20 0.38
▸ TRPA1 O75762 1/20 0.38
▸ PTGS1 P23219 1/20 0.38
▸ CACNA1C Q13936 1/20 0.38
▸ JMJD6 Q6NYC1 3/20 0.34
▸ S1PR2 O95136 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ HTT P42858 1/20 0.33
▸ JAK2 O60674 3/20 0.32
▸ JAK1 P23458 3/20 0.32
▸ TYK2 P29597 3/20 0.32
▸ JAK3 P52333 3/20 0.32
▸ ROCK2 O75116 1/20 0.32
▸ ROCK1 Q13464 1/20 0.32
▸ CDC42BPB Q9Y5S2 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.31
▸ PKM P14618 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3448871 0.79 KMT2A (0.42) LMNAKEAP1KMT2APTGS1JMJD6
SCHEMBL27316377 0.76 USP7 (0.44) LMNAKEAP1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL20676163 0.75 LMNA (0.77) LMNATRPA1PTGS1CACNA1CSMN1; SMN2
SCHEMBL11916170 0.75 CYP1A2 (0.40) LMNAKEAP1KMT2AJMJD6S1PR2
SCHEMBL11951635 0.73 LMNA (0.47) LMNATRPA1PTGS1CACNA1CSMN1; SMN2
SCHEMBL9258776 0.73 KEAP1 (0.66) LMNAKEAP1KMT2ASMN1; SMN2L3MBTL1
SCHEMBL18730149 0.72 LMNA (0.50) LMNAKMT2ATRPA1PTGS1CACNA1C
SCHEMBL10416092 0.72 LMNA (0.86) LMNATRPA1PTGS1CACNA1CSMN1; SMN2
SCHEMBL10080949 0.71 KMT2A (0.56) KEAP1KMT2AJMJD6JAK2
SCHEMBL25605943 0.71 JMJD6 (0.54) KEAP1KMT2AJMJD6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170145011-A1 Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMA (US) 2017-05-25 — — US disclosed
US-20170145011-A1 Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMA (US) 2017-05-25 — — US disclosed
US-9511067-B2 Substituted spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]s as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-12-06 — — US disclosed
US-20150174127-A1 Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2015-06-25 — — US disclosed
US-8916565-B2 Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-12-23 — — US disclosed
US-20120196869-A1 PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2012-08-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150174127-A1 Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels KCNJ2, KCNJ5, KCNJ1 LMNA 3281/4885KEAP1 887/4885KMT2A 2577/4885
US-20170145011-A1 Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels KCNJ2, KCNJ5, KCNJ1 LMNA 3281/4885KEAP1 887/4885KMT2A 2577/4885
US-20120196869-A1 PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS KCNJ2, KCNJ5, KCNJ1 LMNA 3281/4885KEAP1 887/4885KMT2A 2577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback